CVS Health Yönetim

Yönetim kriter kontrolleri 3/4

CVS Health's CEO'su Karen Lynch, Feb2021 tarihinde atandı, in görev süresi 3.67 yıldır. in toplam yıllık tazminatı $ 21.62M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.9% maaş ve 93.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.04% ine doğrudan sahiptir ve bu hisseler € 28.75M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.6 yıl ve 6.7 yıldır.

Anahtar bilgiler

Karen Lynch

İcra Kurulu Başkanı

US$21.6m

Toplam tazminat

CEO maaş yüzdesi	6.9%
CEO görev süresi	3.7yrs
CEO sahipliği	0.04%
Yönetim ortalama görev süresi	2.6yrs
Yönetim Kurulu ortalama görev süresi	6.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Karen Lynch'un ücretlendirmesi CVS Health'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$7b
Dec 31 2023	US$22m	US$2m	US$8b
Sep 30 2023	n/a	n/a	US$9b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$4b
Dec 31 2022	US$21m	US$1m	US$4b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$8b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$20m	US$1m	US$8b
Sep 30 2021	n/a	n/a	US$8b
Jun 30 2021	n/a	n/a	US$7b
Mar 31 2021	n/a	n/a	US$7b
Dec 31 2020	US$11m	US$1m	US$7b

Tazminat ve Piyasa: Karen 'nin toplam tazminatı ($USD 21.62M ), Austrian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.44M ).

Tazminat ve Kazançlar: Karen 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Karen Lynch (61 yo)

3.7yrs

Görev süresi

US$21,615,034

Tazminat

Ms. Karen Sue Lynch serves as Chief Executive Officer, President and Director at CVS Health Corporation since February 01, 2021. She has extensive experience in the health care industry. She was Executive...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Karen Lynch	President	3.7yrs	US$21.62m	0.040% € 28.1m
Thomas Cowhey	Executive VP & CFO	less than a year	US$4.58m	0.0028% € 2.0m
Tilak Mandadi	Executive VP of Ventures and Chief Digital	2.3yrs	US$8.88m	0.0032% € 2.2m
Samrat Khichi	Executive VP	1.7yrs	US$11.89m	0.00078% € 545.2k
Prem Shah	Executive VP	2.9yrs	US$8.58m	0.0037% € 2.6m
Vijay Patel	Senior Director of Business Development & CVS Health and Partner & Co-Founder	no data	Veri yok	Veri yok
James Clark	Senior VP	5.9yrs	Veri yok	0.00067% € 468.3k
David Falkowski	Executive VP & Chief Compliance Officer	no data	Veri yok	Veri yok
Heidi Capozzi	Executive VP & Chief People Officer	less than a year	Veri yok	Veri yok
J. Joyner	Executive Vice President & President of CVS Caremark	1.8yrs	Veri yok	0.0032% € 2.3m
Michelle Peluso	Executive VP and Chief Customer & Experience Officer	3.8yrs	Veri yok	0.0099% € 6.9m
Joneigh Khaldun	VP & Chief Health Equity Officer	3yrs	Veri yok	Veri yok

2.6yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: CVS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Karen Lynch	President	3.7yrs	US$21.62m	0.040% € 28.1m
J. Kirby	Independent Director	less than a year	US$195.42k	0.00045% € 314.6k
Roger Farah	Independent Chairman	5.9yrs	US$576.50k	0.00033% € 230.7k
Mary Schapiro	Independent Director	7.4yrs	US$301.50k	0.00094% € 657.1k
Nancy-Ann DeParle	Independent Director	11.1yrs	US$321.50k	0.0025% € 1.8m
Anne Finucane	Independent Director	13.8yrs	US$321.50k	0.0026% € 1.8m
C. Brown	Independent Director	17.6yrs	US$321.50k	0.0097% € 6.7m
Jean-Pierre Millon	Independent Director	17.6yrs	US$321.50k	0.0088% € 6.1m
Alecia DeCoudreaux	Independent Director	9.6yrs	US$301.50k	0.00024% € 167.8k
Fernando Aguirre	Independent Director	5.9yrs	US$318.17k	0.0028% € 2.0m
Jeffrey Balser	Independent Director	2.1yrs	US$301.50k	0.00058% € 405.4k
Michael Mahoney	Independent Director	less than a year	US$167.50k	0.0011% € 754.9k

6.7yrs

Ortalama Görev Süresi

67.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CVS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.7 yıldır).

CVS Health Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

CVS Health Announces CEO Changes

CVS Health Corporation Appoints Heidi Capozzi as Executive Vice President, Chief People Officer, Effective September 9, 2024

CVS Health Corporation, Annual General Meeting, May 16, 2024

Executive VP recently sold €2.1m worth of stock

CVS Health Announces Executive Changes

CVS Health Names Mark Santos as President, Aetna Medicaid

Recent updates

CVS Health Announces CEO Changes

CVS Health Reportedly Considers Sale of Its Insurance Business

Upcoming dividend of US$0.67 per share

Second quarter dividend of US$0.67 announced

CVS Health Announces Quarterly Dividend, Payable on November 1, 2024

Adherence Files Lawsuit Against CVS Health and Asembia for Alleged Unauthorized Use of Its Trademarked and Copyrighted Intellectual Property

CVS Health Announces Updated Flu and COVID-19 Vaccinations Now Available at CVS Pharmacy® and MinuteClinic®

CVS Health Corporation Appoints Heidi Capozzi as Executive Vice President, Chief People Officer, Effective September 9, 2024

Second quarter 2024 earnings released: EPS: US$1.41 (vs US$1.48 in 2Q 2023)

CVS Health Corporation Revises Earnings Guidance for the Full Year 2024

CVS Health Corporation Launches First-Of-Its-Kind Initiative to Support Patients Most Vulnerable to Health Impacts of Extreme Weather Events

First quarter dividend of US$0.67 announced

CVS Health Announces Quarterly Dividend, Payable on August 1, 2024

Investor sentiment deteriorates as stock falls 19%

The Law Firms of Kessler Topaz Meltzer & Check, LLP and Carella, Byrne, Cecchi, Brody & Agnello, P.C. Files a Class Action Lawsuit Against CVS Health Corporation and Related Entities for Preventing SilverScript Members from Accessing Certain Generic Medications

First quarter 2024 earnings released: EPS: US$0.88 (vs US$1.67 in 1Q 2023)

CVS Health Corporation Revises Earnings Guidance for the Full Year 2024

Upcoming dividend of US$0.67 per share

CVS Health Corporation, Annual General Meeting, May 16, 2024

CVS Health Corporation to Report Q1, 2024 Results on May 01, 2024

Fourth quarter dividend of US$0.67 announced

Cvs Health Approves Quarterly Dividend on the Common Stock, Payable on May 1, 2024

Wisner Baum Files Multiple Class Actions Alleging Several Companies Sold Benzoyl Peroxide Acne Products Without Warning Consumers That They Contain Unsafe Levels of Benzene, a Potent Human Carcinogen

Executive VP recently sold €2.1m worth of stock

Full year 2023 earnings released: EPS: US$6.49 (vs US$3.16 in FY 2022)

Upcoming dividend of US$0.67 per share at 3.1% yield

CVS Health Corporation Provides Earnings Guidance for the Year 2023

CVS Health Announces Executive Changes

Robbins Geller Rudman & Dowd LLP and Aqualaw PLC Reaches Settlements in Class Action with Costco Wholesale Corporation, CVS Health Corporation, The Procter & Gamble Company, Target Corporation, Walgreen Co. and Walmart Inc

CVS Health Approves Quarterly Dividend, Payable on February 1, 2024

CVS Health Names Mark Santos as President, Aetna Medicaid

Third quarter 2023 earnings released: EPS: US$1.76 (vs US$2.60 loss in 3Q 2022)

CVS Health Corporation Revises Earnings Guidance for the Full Year 2023

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş